Nyxoah SA (NYXH): Price and Financial Metrics
GET POWR RATINGS... FREE!
NYXH Stock Price Chart Interactive Chart >
NYXH Price/Volume Stats
| Current price | $10.07 | 52-week high | $37.00 |
| Prev. close | $9.76 | 52-week low | $9.33 |
| Day low | $9.97 | Volume | 7,700 |
| Day high | $10.87 | Avg. volume | 3,596 |
| 50-day MA | $14.53 | Dividend yield | N/A |
| 200-day MA | $22.05 | Market Cap | 251.18M |
Nyxoah SA (NYXH) Company Bio
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest NYXH News From Around the Web
Below are the latest news stories about Nyxoah SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Information on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 11, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares. Share capital: EUR 4,431,664.69 Total number of securities carrying voting rights: 25,797,3 |
Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Mont-Saint-Guibert, Belgium – February 4, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conf |
Nyxoah Provides General Corporate UpdateNyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implant |
Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual V |
Nyxoah appoints new CFONyxoah appoints new CFO Mont-Saint-Guibert, Belgium – November 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Loïc Moreau will join Nyxoah as CFO as of January 1, 2022. Loïc will join Nyxoah from GSK, where he held leadership roles in Finance across various geographies. Prior t |
NYXH Price Returns
| 1-mo | N/A |
| 3-mo | -47.39% |
| 6-mo | -56.22% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...